Posted by Michael Wonder on 25 Sep 2023
UCB announces approval of Rystiggo (rozanolixizumab) and Zilbryso (zilucoplan) for the treatment of adult patients with generalised myasthenia gravis in Japan
25 September 2023 - Approvals are based on pivotal phase 3 data for both medicines, showing statistical and clinically relevant improvements in gMG-specific outcomes.
UCB today announced that the Japanese Ministry of Health, Labour and Welfare has granted approval for Rystiggo (rozanolixizumab) and for Zilbryso (zilucoplan), for the treatment of generalised myasthenia gravis in adult patients (only for patients who inadequately respond to steroids or other immunosuppressants).
